Skip to main content

Table 3 Effect of daily home fortification with 3 mg iron as NaFeEDTA and 12.5 mg iron as encapsulated ferrous fumarate on continuous outcomes at 30 days after start of intervention, per protocol analysis

From: Daily home fortification with iron as ferrous fumarate versus NaFeEDTA: a randomised, placebo-controlled, non-inferiority trial in Kenyan children

Outcome/intervention group No. (n) Estimatea Effect (95% CI) relative to placebob Effect (95% CI) relative to standardb
Haemoglobin concentration
 Placebo 105 106.9 g/L (13.3 g/L) Reference Not applicable
 Iron, 3 mg as NaFeEDTA 103 110.0 g/L (12.5 g/L) 3.0 g/L (–0.2 g/L to 6.2 g/L)c 1.3 g/L (–1.8 g/L to 4.3 g/L)c
 Iron, 12.5 mg as ferrous fumarate 107 108.6 g/L (12.0 g/L) 1.6 g/L (–1.6 g/L to 4.8 g/L)c Reference
Plasma ferritin concentration
 Placebo 104 29.7 μg/L [3.47] Reference Not applicable
 Iron, 3 mg as NaFeEDTA 102 33.7 μg/L [2.53] 16.2% (–14.3% to 57.7%)d 2.5% (–22.4% to 35.4%)d
 Iron, 12.5 mg as ferrous fumarate 105 32.6 μg/L [3.00] 12.3% (–17.1% to 52.0%)d Reference
Plasma soluble transferrin receptor concentration
 Placebo 105 2.24 mg/L [1.61] Reference Not applicable
 Iron, 3 mg as NaFeEDTA 103 2.15 mg/L [1.47] –4.3% (–13.5% to 5.9%)d 3.6% (–5.5% to 13.6%)d
 Iron, 12.5 mg as ferrous fumarate 106 2.07 mg/L [1.38] –7.3% (–16.2% to 2.6%)d Reference
Erythrocyte ZPP-haem ratio
 Placebo 104 136 μmol/mol [2.17] Reference Not applicable
 Iron, 3 mg as NaFeEDTA 103 127 μmol/mol [1.97] –6.5% (–23.5% to 14.2%)d -5.3% (-21.7% to 14.5%) d
 Iron, 12.5 mg as ferrous fumarate 106 134 μmol/mol [2.00] –0.7% (–18.6% to 21.0%)d Reference
  1. aMean (SD) or geometric mean [geometric standard deviation]
  2. bEffects were adjusted for study design (blocks nested within strata of haemoglobin concentration <100 g/L and ≥100 g/L)
  3. cEffects were calculated as absolute difference in means
  4. dExponentiation of group differences with log-transformed outcomes resulted in associations being expressed as relative differences